Table 2.
Univariate HRs with 95% CIs and DMFS in CAB risk categories of various clinical sub-groups.
| No of patients | Hazard Ratio (95% CI) | Low-risk |
High-risk |
|||||
|---|---|---|---|---|---|---|---|---|
| % | DMFS as % ± SE | % | DMFS as % ± SE | |||||
| CanAssist Breast | Cohort | Total (Chemo endocrine+Endocrine therapy alone) | 925 | 3.09 (1.83–5.21) | 72 | 95.03 ± 0.84 | 28 | 85.31 ± 2.2 |
| Endocrine therapy alone | 196 | 6.51 (1.53–27.62) | 78 | 97.372 ± 1.29 | 22 | 83.59 ± 5.67 | ||
| Node and tumor | Node-negative | 513 | 2.57 (0.97–6.7) | 81 | 95.88 ± 0.98 | 19 | 89.66 ± 3 | |
| Node-positive | 411 | 2.45 (1.34–4.47) | 61 | 92.82 ± 1.62 | 39 | 83.11 ± 2.96 | ||
| T1 tumors | 223 | 3.34 (0.86–12) | 79 | 96 ± 1.46 | 21 | 86.95 ± 4.9 | ||
| T2 tumors | 642 | 2.79 (1.49–5.24) | 74 | 94.48 ± 1 | 26 | 85.29 ± 2.72 | ||
| Age | Age ≤ 50 years | 355 | 3.14 (1.39–7) | 74 | 94.3 ± 1.4 | 26 | 82.95 ± 3.8 | |
| Age ≤ 50 years, T2 | 246 | 3.07 (1.11–8.49) | 76 | 94.11 ± 1.7 | 24 | 83 ± 4.89 | ||
| Age ≤ 50 years, G3 | 146 | 2.79 (0.76–10.2) | 64 | 95.45 ± 2.08 | 36 | 88.46 ± 4.4 | ||
| Age > 50 years | 562 | 2.75 (1.31–5.76) | 72 | 95.77 ± 1 | 28 | 88.66 ± 2.5 | ||
| Clinically low risk | T≤ 5cmN0, Total | 486 | 2 .48(0.79–7.8) | 84 | 96.3 ± 0.94 | 16 | 91 ± 3.24 | |
| T≤ 5cmN0, Endocrine therapy alone | 152 | 10.9 (1.4–84) | 86 | 97.66 ± 1.33 | 14 | 77.27 ± 8.9 | ||
| T≤2cmN0, Total | 143 | 5.33 (0.32–86) | 89 | 97.62 ± 1.36 | 11 | 87.5 ± 8.3 | ||
| Luminal A | 263 | 4.54 (1–19.75) | 81 | 97.19 ± 1.13 | 19 | 87.75 ± 4.68 | ||
| Clinically high risk | Luminal B | 469 | 3.24 (1.69–6.22) | 74 | 93.34 ± 1.34 | 26 | 79.65 ± 3.63 | |
| T2N1 | 299 | 2.65 (1.31–5.36) | 64 | 92.66 ± 1.88 | 36 | 81.47 ± 3.74 | ||
| as per monarchE trial | 265 | 2.44 (1.2–4.94) | 53 | 92.87 ± 2.17 | 47 | 83.18 ± 3.34 | ||
| Luminal subtypes (A-low risk; B-high risk) | 732 | 2.31 (1.37–3.91) | 36 | 95.43 ± 1.29 | 64 | 89.45 ± 1.4 | ||
Abbreviations: HR-Hazard ratio, DMFS-distant metastasis free survival, CAB-CanAssist Breast.